Safety of Alopecia Treatments in Patients With Breast Cancer and High-Risk Women: A Review

    Caitlin A. Kearney, Anna Brinks, Carli D. Needle, Grace Rachko, Amy Kalowitz Bieber, Jerry Shapiro, Mario E. Lacouture, Daniela Majerson, Kristen I. Lo Sicco
    Image of study
    TLDR Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
    The review evaluates the safety of alopecia treatments in breast cancer patients and high-risk women, focusing on antiandrogens, 5α-reductase inhibitors, and spironolactone. It concludes that 5α-reductase inhibitors and spironolactone, used for androgenetic alopecia, do not elevate the risk of breast or gynecologic cancers, even for those on endocrine therapies for breast cancer. Additionally, ketoconazole and low-level light therapy are discussed as supportive treatments. The findings indicate that these treatments are generally safe for managing alopecia in this patient group without increasing cancer risk.
    Discuss this study in the Community →

    Research cited in this study

    66 / 66 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    5 / 1000+ results